Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16046-

  Miyanohara, Atsushi ^a   Kamizato, Kota ^a   Juhas, Stefan ^b   Juhasova, Jana ^b   Navarro, Michael ^a   Marsala, Silvia ^a   Lukacova, Nada ^c   Hruska Plochan, Marian ^d   Curtis, Erik ^e   Gabel, Brandon ^e   Ciacci, Joseph ^e   Ahrens, Eric T ^f   Kaspar, Brian K ^g   Cleveland, Don ^h,i   Marsala, Martin ^a,c  

^a School of Medicine   (United States)

^b INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^c Center of Excellence for Brain Research   (Slovakia)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS 9; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AXON; BRAIN STEM; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENE TARGETING; GLIA CELL; GRAY MATTER; IN VIVO STUDY; MALE; MOTOR CORTEX; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SPINAL CORD; TRANSGENE; VIRAL GENE THERAPY; VIRUS ENTRY; WHITE MATTER; DRUG FORMULATION; IN VIVO GENE TRANSFER; PIA MATER; PORCINE MODEL; VIRAL GENE DELIVERY SYSTEM;

ADENO ASSOCIATED VIRUS VECTOR; DEXTRAN; GREEN FLUORESCENT PROTEIN;

EID: 85015239684     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.46     Document Type: Article

References (18)

1. 1 Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM, Kaspar, BK, Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27 (2009), 59–65.
2. 2 Duque, S, Joussemet, B, Riviere, C, Marais, T, Dubreil, L, Douar, AM, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17 (2009), 1187–1196.
3. 3 Gray, SJ, Matagne, V, Bachaboina, L, Yadav, S, Ojeda, SR, Samulski, RJ, Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19 (2011), 1058–1069.
4. 4 Meyer, K, Ferraiuolo, L, Schmelzer, L, Braun, L, McGovern, V, Likhite, S, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther 23 (2015), 477–487.
5. 5 Foust, KD, Salazar, DL, Likhite, S, Ferraiuolo, L, Ditsworth, D, Ilieva, H, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 21 (2013), 2148–2159.
6. 6 Passini, MA, Bu, J, Richards, AM, Treleaven, CM, Sullivan, JA, O'Riordan, CR, et al. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 25 (2014), 619–630.
7. 7 Bell, P, Hinderer, C, Louboutin, JP, Yu, H, Grant, R, Bote, E, et al. Motor neuron transduction after intracisternal delivery of AAV9 in a cynomolgus macaque. Hum Gene Ther Methods 26 (2015), 43–44.
8. 8 Nihei, K, McKee, AC, Kowall, NW, Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 86 (1993), 55–64.
9. 9 Conradi, S, Ronnevi, LO, Selective vulnerability of alpha motor neurons in ALS: relation to autoantibodies toward acetylcholinesterase (AChE) in ALS patients. Brain Res Bull 30 (1993), 369–371.
10. 10 Hefferan, MP, Galik, J, Kakinohana, O, Sekerkova, G, Santucci, C, Marsala, S, et al. Human neural stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation. PLoS One, 7, 2012, e42614.
11. 11 Samaranch, L, San Sebastian, W, Kells, AP, Salegio, EA, Heller, G, Bringas, JR, et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 22 (2014), 329–337.
12. 12 Kakinohana, O, Cizkova, D, Tomori, Z, Hedlund, E, Marsala, S, Isacson, O, et al. Region-specific cell grafting into cervical and lumbar spinal cord in rat: a qualitative and quantitative stereological study. Exp Neurol 190 (2004), 122–132.
13. 13 Usvald, D, Vodicka, P, Hlucilova, J, Prochazka, R, Motlik, J, Kuchorova, K, et al. Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplant 19 (2010), 1103–1122.
14. 14 Yaksh, TL, Rudy, TA, Analgesia mediated by a direct spinal action of narcotics. Science 192 (1976), 1357–1358.
15. 15 Xu, Q, Chou, B, Fitzsimmons, B, Miyanohara, A, Shubayev, V, Santucci, C, et al. In vivo gene knockdown in rat dorsal root ganglia mediated by self-complementary adeno-associated virus serotype 5 following intrathecal delivery. PLoS One, 7, 2012, e32581.
16. 16 Xiao, X, Li, J, Samulski, RJ, Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72 (1998), 2224–2232.
17. 17 Basso, DM, Beattie, MS, Bresnahan, JC, A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12 (1995), 1–21.
18. 18 Navarro, R, Juhas, S, Keshavarzi, S, Juhasova, J, Motlik, J, Johe, K, et al. Chronic spinal compression model in minipigs: a systematic behavioral, qualitative, and quantitative neuropathological study. J Neurotrauma 29 (2012), 499–513.